Global tuberculosis drug development pipeline: the need and the reality

Z Ma, C Lienhardt, H McIlleron, AJ Nunn, X Wang - The Lancet, 2010 - thelancet.com
Drugs for tuberculosis are inadequate to address the many inherent and emerging
challenges of treatment. In the past decade, ten compounds have progressed into the …

New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects

AI Zumla, SH Gillespie, M Hoelscher… - The Lancet infectious …, 2014 - thelancet.com
About 1· 3 million people died of tuberculosis in 2012, despite availability of effective drug
treatment. Barriers to improvements in outcomes include long treatment duration (resulting …

[HTML][HTML] UK controlled trial of intrapleural streptokinase for pleural infection

NA Maskell, CWH Davies, AJ Nunn… - … England Journal of …, 2005 - Mass Medical Soc
Background Intrapleural fibrinolytic agents are used in the drainage of infected pleural-fluid
collections. This use is based on small trials that did not have the statistical power to …

[HTML][HTML] Intrapleural use of tissue plasminogen activator and DNase in pleural infection

NM Rahman, NA Maskell, A West, R Teoh… - … England Journal of …, 2011 - Mass Medical Soc
Background More than 30% of patients with pleural infection either die or require surgery.
Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy …

A systematic review of the use of dosage form manipulation to obtain required doses to inform use of manipulation in paediatric practice

RH Richey, C Hughes, JV Craig, UU Shah… - International journal of …, 2017 - Elsevier
This study sought to determine whether there is an evidence base for drug manipulation to
obtain the required dose, a common feature of paediatric clinical practice. A systematic …

[HTML][HTML] Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis

SH Gillespie, AM Crook, TD McHugh… - … England Journal of …, 2014 - Mass Medical Soc
Background Early-phase and preclinical studies suggest that moxifloxacin-containing
regimens could allow for effective 4-month treatment of uncomplicated, smear-positive …

[HTML][HTML] High-dose rifapentine with moxifloxacin for pulmonary tuberculosis

A Jindani, TS Harrison, AJ Nunn… - … England Journal of …, 2014 - Mass Medical Soc
Background Tuberculosis regimens that are shorter and simpler than the current 6-month
daily regimen are needed. Methods We randomly assigned patients with newly diagnosed …

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up

JP Zajicek, HP Sanders, DE Wright… - Journal of Neurology …, 2005 - jnnp.bmj.com
Objective: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis
(MS), in a follow up to the main Cannabinoids in Multiple Sclerosis (CAMS) study. Methods …

[HTML][HTML] Treatment strategy for rifampin-susceptible tuberculosis

NI Paton, C Cousins, C Suresh, E Burhan… - … England Journal of …, 2023 - Mass Medical Soc
Background Tuberculosis is usually treated with a 6-month rifampin-based regimen.
Whether a strategy involving shorter initial treatment may lead to similar outcomes is …

Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial

C Chintu, GJ Bhat, AS Walker, V Mulenga, F Sinyinza… - The Lancet, 2004 - thelancet.com
Background No trials of co-trimoxazole (trimethoprim-sulfamethoxazole) prophylaxis for HIV-
infected adults or children have been done in areas with high levels of bacterial resistance …